Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 3pembrolizumab 2Melphalan 2utomilumab 1tislelizumab 1spartalizumab 1niraparib 1montanide ISA 51 1entinostat 1binimetinib 1Toll-Like Receptor 1 1Rose Bengal 1Protein Kinase C 1Nivolumab 1Interleukin-2 1Injections 1Imatinib Mesylate 1Cryosurgery 1Crizotinib 1Blood Specimen Collection 1Bevacizumab 1Amplified Fragment Length Polymorphism Analysis 1ADI PEG20 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Toll-Like Receptor 1 × Gastrointestinal × Clear all
NCT05576077 2025-03-10

STARLING

Turnstone Biologics, Corp.

Phase 1 Terminated
31 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡